Armenta Bioscience ApS
CVRCVR number42358444
Company financials
Key figures
Updated 20 May 2026
- Return on assets
- -159.4%
- Return on equity
- -111.6%
- Current ratio
- 1,083.3%
- Equity ratio
- 91.8%
Profit and loss
| Reporting period | |
|---|---|
Gross profit | -676,873 |
Operating profit | -2,228,976 |
Finance expenses | 23 |
Tax expense | -795,546 |
Profit/loss for the year | -1,433,453 |
Employees
| Reporting period | |
|---|---|
Avg. employees | 4 |
Personnel costs | 1,539,026 DKK |
Balance sheet
| Reporting period | |
|---|---|
Cash and cash equivalents | 676,001 |
Current assets | 1,239,907 |
Non-current assets | 158,545 |
Total assets | 1,398,452 |
Equity | 1,283,993 |
Liabilities | 114,459 |
Current liabilities | 114,459 |
Working capital
| Reporting period | |
|---|---|
Other current receivables | 96,437 |
Trade payables | 64,621 |
Capital and dividend
| Reporting period | |
|---|---|
Contributed capital | 51,517 |
Retained earnings | 1,232,476 |
Investments and assets
| Reporting period | |
|---|---|
Long-term investments and receivables | 46,297 |
Property, plant and equipment | 112,248 |
Annual report highlights
Official annual report · 2025
Business and development
Primary activities
The company's main activities include conducting business and biotechnological research in
sustainable foods.
Commitments and security
Contingent liabilities
The company has entered into lease agreements with a termination notice period of 1–3 months. The monthly obligation amounts to TDKK 25, and the remaining obligation amounts to TDKK 68 during the notice period.
Create a free account to see up to 9 years of financial history
Create free account